
Asterias Biotherapeutics adds two to board
pharmafile | August 26, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |ย ย Asterias Biotherapeutics, Pfizerย
US biotech firm Asterias Biotherapeutics has confirmed the appointments of Andrew Arno and Natale Ricciardi to its board of directors.
Natale Ricciardi (pictured) joins the company having spent his entire 39-year biopharma career at Pfizer. He retired in 2011 as a member of its executive leadership team after holding the positions of president of Pfizer global manufacturing, and as a senior VP.
In addition to his corporate leadership role at the firm, he was directly responsible for all Pfizerโs internal and external supply organisation.
Arno joins the company with 30 years of experience working with emerging growth companies. He is currently managing director of investment bank Emerging Growth Equities.
He was previously president of LOMUSA, also an investment banking firm. From 2009 to 2012 he served as vice chairman and CMO of Unterberg Capital, an investment advisory firm that he co-founded.
โWe are very pleased to welcome Andy Arno and Nat Ricciardi to our board and look forward to working with them to build shareholder value,โ says Alfred Kingsley, chairman at Asterias.
Related Content
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






